Largest Plasma Glycome GWAS Uncovers Liver and Immune Disease Connections

N-glycosylation — the attachment of complex sugar chains to proteins — affects more than half of all plasma proteins and plays a critical role in immune signaling, protein folding, and disease pathogenesis. Most glycosylated plasma proteins are synthesized and secreted by the liver and lymphoid tissues, making this process highly relevant to metabolic and inflammatory conditions. Despite growing evidence linking altered glycosylation to liver disease, cardiovascular conditions, and immune disorders, the genetic architecture governing plasma N-glycosylation has remained poorly characterized.

To address this gap, the authors performed a large-scale GWAS of N-glycosylation traits measured in blood plasma from approximately 10,000 individuals drawn from multiple European cohorts including TwinsUK, UK Biobank, and others. Plasma N-glycan profiles were measured using high-throughput liquid chromatography and mass spectrometry. The study analyzed dozens of derived glycan traits reflecting galactosylation, sialylation, fucosylation, and branching patterns across the total plasma glycome.

The study identified 16 novel genetic loci associated with plasma N-glycosylation, doubling the number previously known. Thirteen novel prioritized genes emerged, including GCKR and TRIB1 — both strongly implicated in nonalcoholic fatty liver disease and metabolic syndrome — as well as HP (haptoglobin), SERPINA1 (alpha-1 antitrypsin), and CFH (complement factor H). These genes are predominantly liver-expressed, and several encode major glycoproteins themselves, suggesting a feedback loop where genetic variation affects both glycoprotein abundance and their glycan modification patterns.

By integrating multi-omics data — including plasma proteomics, liver transcriptomics, and known disease associations — the authors traced mechanistic pathways from genetic variant to glycan trait to disease outcome. GCKR and TRIB1 loci, for example, linked plasma glycan variation to lipid metabolism and NAFLD risk. HP and SERPINA1 associations connected glycosylation to acute-phase inflammatory response and anti-protease activity, while CFH pointed toward complement-mediated immune regulation. These connections suggest that glycan traits could serve as intermediate phenotypes bridging genetic risk to clinical disease.

The study provides an openly accessible multi-omics resource for the research community. Limitations include the predominantly European ancestry of participants, which may limit generalizability, and the use of total plasma glycomics rather than protein-specific glycan profiling, which limits direct attribution of signals to individual glycoproteins. Nonetheless, this work represents a major advance in understanding the genetic regulation of the human glycome and its role in aging-related and inflammatory diseases.